Newer opportunities in systemic therapy of lung cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Rajan, A ^a   Gutierrez, M ^a   Giaccone, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BOSUTINIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CP 751871; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; K RAS PROTEIN; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VORINOSTAT; XL 647; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER CELL CULTURE; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENZYME INHIBITION; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; ARTICLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; LUNG TUMOR; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53449089650     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn445     Document Type: Conference Paper

References (52)

1. Rowinsky EK. The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-457.
2. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007; 2: 327-343.
3. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-call lung cancer. J Clin Oncol 2007; 25: 587-595.
4. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: An evolving story. Annu Rev Med 2008; 59: 429-442.
5. Shepherd FA, Rodriguez Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.
6. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
7. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: E17.
8. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2(3): E73.
9. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
10. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-7670.
11. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Oncologist 2007; 12: 325-330.
12. O'Byrne KJ, Koukourakis MI, Giatromanolaki A. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82: 1427-1432.
13. Shimanuki Y, Takahashi K, Cui R et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for nonsmall cell lung cancer. Lung 2005; 183: 29-42.
14. Gutierrez M, Giaccone G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr Opin Oncol 2008; 20: 176-182.
15. Takayama K, Ueno H, Nakanishi Y et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000; 60: 2169-2177.
16. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
17. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non-small cell lung cancer. Clin Cancer Res 2007; 13: S4623-4627.
18. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2008; 26: 1871-1878.
19. Herbst R, O'Neill V. Fehrenbacher L et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. [abstract #53]. Eur J Cancer Suppl 2006: 4 20.
20. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
21. Taguchi F, Koh Y, Koizumi F et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa" -sensitive and resistant xenograft models. Cancer Sci 2004; 95: 984-989.
22. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
23. Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung cancer [abstract]. J Clin Oncol 2006; 24(18S): 7002.
24. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor (beta) in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
25. O'Farrell A-M, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
26. Brahmer JR, Govindan R, Novello S et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study [abstract]. J Clin Oncol 2007; 25(18S): 7542.
27. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(4): 650-656.
28. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and functon of Src kinase. Oncogene 2000; 19(49): 5620-5635.
29. c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 1992; 28(2-3): 372-377.
30. Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol 2008 Apr3; [Epub ahead of print).
31. Maa MC, Leu TH, McCarley DJ et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implication for the etiology of multiple human cancers. Proc Natl Acad Sci USA 1995; 92: 6981-6985.
32. Song L, Morris M, Bagui T et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-5548.
33. Qin B, Ariyama H, Baba E et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma. cells. Cancer Chemother Pharmacol 2006; 58: 577-584.
34. Witta SE, Gemmill RM, Hirsch FR etal. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944-950.
35. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
36. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-6932.
37. Senju M, Sueoka N, Sato A et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 2006; 132: 150-158.
38. Bishop SC, Burlison JA, Blagg BS. Hsp90: A novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 2007; 7: 369-388.
39. Gallegos Ruiz MI, Floor K, Roepman P et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE 2008; 3(3): E0001722.
40. Sawai A, Chandarlapaty S, Greulich H. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008; 68(2): 589-596.
41. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: A powerful new tool for lung cancer diagnosis. Oncogene 2002; 21(35): 5450-5461.
42. Komatsu N, Kawamata N, Takeuchi S et al. SAHA,a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncology Rep 2006; 15(1): 187-191.
43. Park JH, Kim SH, Choi MC et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368(2): 318-322.
44. Hiyama K, Hiyama E, Ishioka S et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
45. Dikmen ZG, Gellert GC, Jackson S et al. In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-7873.
46. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
47. Yang Y, Wislez M, Fujimoto N et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008; 7: 952-960.
48. Karamouzis MV, Papavassiliou AG. The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med 2006; 12: 595-602.
49. Karp DD, Paz-Ares LG, Blakely LJ et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2007; 25(18S): 7506.
50. Viktorsson K, Lewensohn R. Apoptotic signaling pathways in lung cancer. J Thorac Oncol 2007; 2: 175-179.
51. Voortman J, Resende TP. Abou El Hassan MA et al. TRAIL therapy in non-small cell lung cancer cells: Sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6: 2103-2112.
52. Nemunaitis JJ. Are vaccines making a comeback in non-small-cell lung cancer? J Clin Oncol 2008; 26: 1402-1403.